Literature DB >> 23784674

Attitude towards second-generation antipsychotics among patients with schizophrenia and their relatives.

M S Karthik1, Parmanand Kulhara, Subho Chakrabarti.   

Abstract

OBJECTIVE: Given the paucity of research in this area, this study attempted to assess attitudes towards second-generation antipsychotic medications and their correlates among the patients with schizophrenia and their relatives.
METHODS: Structured assessments of attitudes to medications, psychopathology, insight/knowledge, side effects, functioning and treatment satisfaction were carried out in a random sample of 50 patients with DSM-IV schizophrenia and their relatives. All, except one of the patients, were on second-generation antipsychotics.
RESULTS: Most patients had positive attitudes towards second-generation antipsychotics. Severity of positive symptoms and higher burden of side effects (e.g. sexual dysfunction, weight gain and sedation) emerged as the principal correlates of negative attitudes among patients. Greater awareness of illness, being employed, better social functioning and greater treatment satisfaction were all associated with positive attitudes among patients. Relatives had significantly more positive attitudes towards antipsychotics than patients and were more satisfied with the treatment. They were well informed about the illness, and their level of knowledge had a significant association with positive attitudes.
CONCLUSIONS: Effective antipsychotic treatment, which improves functioning and minimises side effects could lead to more favourable attitudes towards antipsychotics among patients. Increasing awareness of illness, enhancing treatment satisfaction and involving relatives in treatment could also be of help.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  attitudes; patients; relatives; schizophrenia; second-generation antipsychotics

Mesh:

Substances:

Year:  2013        PMID: 23784674     DOI: 10.1002/hup.2332

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  4 in total

1.  Attitudes toward metabolic adverse events among patients with schizophrenia in Japan.

Authors:  Norio Sugawara; Norio Yasui-Furukori; Manabu Yamazaki; Kazutaka Shimoda; Takao Mori; Takuro Sugai; Hiroshi Matsuda; Yutaro Suzuki; Yoshitake Minami; Yuji Ozeki; Kurefu Okamoto; Toyoaki Sagae; Toshiyuki Someya
Journal:  Neuropsychiatr Dis Treat       Date:  2016-02-24       Impact factor: 2.570

2.  Lack of tolerable treatment options for patients with schizophrenia.

Authors:  Leslie Citrome; Anna Eramo; Clement Francois; Ruth Duffy; Susan N Legacy; Steve J Offord; Holly B Krasa; Stephen S Johnston; Alice Guiraud-Diawara; Siddhesh A Kamat; Patricia Rohman
Journal:  Neuropsychiatr Dis Treat       Date:  2015-12-16       Impact factor: 2.570

3.  Assessing the burden of treatment-emergent adverse events associated with atypical antipsychotic medications.

Authors:  Pierre-Michel Llorca; Christophe Lançon; Ann Hartry; T Michelle Brown; Dana B DiBenedetti; Siddhesh A Kamat; Clément François
Journal:  BMC Psychiatry       Date:  2017-02-13       Impact factor: 3.630

4.  Attitudes toward psychotropic medications among patients with chronic psychiatric disorders and their family caregivers.

Authors:  Sandeep Grover; Subho Chakrabarti; Aarti Sharma; Shikha Tyagi
Journal:  J Neurosci Rural Pract       Date:  2014-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.